RBC Capital analyst Leonid Timashev upgraded Design Therapeutics (DSGN) to Outperform from Sector Perform with a price target of $13, up from $6.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DSGN:
- Design Therapeutics Reports Q3 2025 Financial Results
- Design Therapeutics reports Q3 EPS (30c), consensus (34c)
- Design Therapeutics Advances DT-168 Study for Fuchs Dystrophy
- Design Therapeutics Advances DT-216P2 Study for Friedreich’s Ataxia
- Design Therapeutics Advances with New Study on DT-216P2 for Friedreich Ataxia